Compare · head to head
South Bow vs Xeris Pharmaceuticals
Xeris Pharmaceuticals ranks higher overall — 360 rank 70 vs 22.
South Bow leads on Value (45 vs 39). Xeris Pharmaceuticals leads on Growth (76 vs 39), Safety (35 vs 29) and Sentiment (52 vs 42). The two are close on Quality.
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | Canada | USA |
| Sector | Energy & Oil | Health Care |
| Industry | Oil, Gas & Consumable Fuels | Pharmaceuticals |
| Size | Medium | Small |
| ISIN | CA83671M1059 | US98422E1038 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 22 | 70 |
| Value | 45 | 39 |
| Quality | 65 | 69 |
| Growth | 39 | 76 |
| Safety | 29 | 35 |
| Sentiment | 42 | 52 |
| Quality details | ||
| Profitability | 59 | 65 |
| Cash Truth | 71 | 72 |
South Bow vs SuncorSouth Bow vs MedlineSouth Bow vs Knife RiverSouth Bow vs Sands ChinaAdd a third stock →
Full analyses: South Bow · Xeris Pharmaceuticals
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100